Contact: Kathryn Ullman
Mount Sinai Press Office
646-605-5950
[email protected]

November Is Diabetes Awareness Month

Mount Sinai Experts Weigh In on Self-Management, Treatment Options, Reversing the Disease and the Newest Advances in Diabetes Research

Newswise — (NEW YORK, NY – November 2, 2018) - Diabetes is the seventh leading cause of death in the United States. Today, more than 30 million people in the United States have diabetes, and one-quarter of them don’t know they have it, according to the U.S. Centers for Disease Control and Prevention.

November is Diabetes Awareness Month and Mount Sinai Health System experts are sharing tips on self-management, treatment options, reversing the disease, and the newest advances in diabetes research.

Experts Available for Interview:

  • Andrea Dunaif, MD, Chief, Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes, and Bone Disease, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System
  • Carol Levy, MD, Clinical Director, Mount Sinai Diabetes Center, The Mount Sinai Hospital
  • Andrew Stewart, MD, PhD, Director, Mount Sinai Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai
  • Ronald Tamler, MD, PhD, Professor, Medicine (Endocrinology, Diabetes, and Bone Disease), Icahn School of Medicine at Mount Sinai; Director, Digital Health Implementation, Mount Sinai Health System
  • David W. Lam, MD, Medical Director, Mount Sinai Clinical Diabetes Institute; Assistant Professor, Medicine (Endocrinology, Diabetes, and Bone Disease), Icahn School of Medicine at Mount Sinai
  • Reshmi Srinath, MD, Director, Weight and Metabolism Management Program, Icahn School of Medicine at Mount Sinai
  • Deena Adimoolam, MD, Assistant Professor, Medicine (Endocrinology, Diabetes, and Bone Disease), Icahn School of Medicine at Mount Sinai
  • Maria Rodriguez, RD, Certified Diabetes Educator, The Diabetes Alliance, Mount Sinai Health System

Rare Tumor May Provide Road Map To Diabetes Therapies:

Dr. Stewart and his team of researchers at the Mount Sinai Diabetes, Obesity, and Metabolism Institute have found a surprising potential ally in the search for a cure for type 1 diabetes.

In the largest genomic study of human insulinomas—rare and usually benign pancreatic beta cell tumors that overproduce insulin—researchers have uncovered multiple pathways to human beta cell proliferation, long seen as a holy grail in treating and possibly curing diabetes. Insulinomas have now become an invaluable tool in the search for diabetes therapies. Over the last two years, this "insulinoma datamine" or "roadmap" has helped to identify two new classes of drugs that are able to make human beta cells regenerate. 

“For the first time, we have a genomic recipe—an actual wiring diagram in molecular terms—that demonstrates how beta cells replicate. This is a major step forward towards replacing the lost beta cells in people with both Type 1 and Type 2 diabetes,” said Dr. Stewart.

To learn more, go to https://www.youtube.com/watch?v=INn_ic6SgYQ&feature=youtu.be

Managing Type 1 Diabetes With the Help of the Dexcom G6 Continuous Glucose Monitor:

Doctors at the Mount Sinai Diabetes Center are offering a new generation of continuous glucose monitors (CGMs), the Dexcom G6. This device is a significant leap in CGM technology. It’s a tiny needle that stays under a patient’s skin for about a week, sending signals about the patient’s blood sugar.

The G6 CGM constantly uploads blood sugar readings to a smartphone, and from there to any loved one or doctor with whom the patient decides to share the data. Another important feature is the ability to set alarms for sugar levels that are too high or too low.

Patients using the new device are available for interview.

Mount Sinai Artificial Pancreas Research Program:

Dr. Levy and her team of researchers at the Icahn School of Medicine at Mount Sinai are studying the safety and efficacy of artificial pancreas systems to improve blood glucose control and reduce the burden of disease for people with type 1 diabetes.

The Mount Sinai Hospital is the first clinical site in Manhattan to use the first FDA-approved artificial pancreas device, Medtronic’s MiniMed 670F hybrid closed looped system.

To learn more go to https://www.youtube.com/watch?v=HKP1VjQg6Jg&t=4s

Type 1 diabetes patients on the artificial pancreas are available for interview.

Symptoms of Diabetes:

  • Frequent urination and blurry vision
  • Unusual thirst and sensations of hunger and fatigue
  • Unintended weight loss
  • Recurrent infections like skin, gum, or bladder infections

Tips for Diabetes Prevention:

  • Make smarter food choices
  • Increase physical activity
  • Maintain a healthy weight
  • Reduce salt and sugar intake

Risk Factors for Prediabetes:

  • Elevated blood glucose levels
  • Family history of diabetes
  • Polycystic ovary syndrome
  • History of gestational diabetes
  • Having hypertension, high cholesterol, or high triglycerides
  • Sedentary lifestyle and obesity and a history of cardiovascular disease

About Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 6,600 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools”, aligned with a U.S. News & World Report’s “Honor Roll” Hospital, it is ranked as a leading medical school for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report’s “Honor Roll” of top U.S. hospitals; it is one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 “Best Hospitals” issue. Mount Sinai’s Kravis Children’s Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.

###